期刊文献+

IL-12联合结核杆菌DNA疫苗初免-BCG加强免疫的免疫效果观察 被引量:2

Immunogenicity of Interleukin 12 and DNA Vaccine Prime-BCG Boost Against Mycobacterium Tuberculosis
下载PDF
导出
摘要 目的研究并比较IL-12联合结核分枝杆菌(TB)DNA(Ag85A和ESAT-6)疫苗初免-BCG加强免疫的应答效果。方法将小鼠随机分成PBS阴性对照组和4组免疫组:BCG组、DNA(Ag85A和ESAT-6)初免-BCG异源加强组、DNA+IL-12初免-BCG异源加强组和DNA初免-BCG+IL-12异源加强组。末次免疫后4、6、8周分别测定血清总IgG水平,同时分离小鼠脾细胞,进行淋巴细胞增殖实验(流式细胞仪检测),测定脾细胞培养上清中IFN-γ分泌水平,并检测小鼠脾脏淋巴细胞表型。结果4组免疫组体外经TB纯蛋白衍生物(TB-PPD)刺激后均检测到特异性IgG抗体产生,且抗体水平在末次免疫后4~8周逐渐增加,4组平均效价为1∶80,1∶120、1∶160、1∶160,各组抗体水平增加无明显差异(P>0.05);小鼠脾细胞体外经TB-PPD刺激后,4组免疫组均能产生特异性淋巴细胞增殖并诱生较强的IFN-γ反应,且DNA+IL-12/BCG和DNA/BCG+IL-12组特异性淋巴细胞增殖活性和IFN-γ分泌水平均明显强于BCG,DNA/BCG组(P<0.05),但DNA+IL-12/BCG和DNA/BCG+IL-12组间差异不明显;4组免疫组小鼠CD4+、CD8+T淋巴细胞较PBS组有较大升高(P<0.05),且DNA+IL-12/BCG和DNA/BCG+IL-12组CD4+、CD8+T淋巴细胞百分比大于BCG以及DNA/BCG组(P<0.05)。结论IL-12联合DNA疫苗初免-BCG加强的免疫策略较BCG免疫以及单纯的DNA疫苗初免-BCG加强免疫能在小鼠体内诱导更强的特异性细胞免疫反应,产生高水平的IFN-γ。 Objective To investigate the immunogenicity of vaccine strategies about human interleukin 12 associated with combined DNA(Ag85A and ESAT-6)prime-BCG boost.Methods BALB/c mice were divided into PBS negative control and 4 immunity groups:BCG group,DNA/BCG group,DNA+IL-12/BCG group and DNA/BCG+IL-12 group.All mice received three immunizations at 2-week interval.Specific IgG antibody in serum of mice was determined with indirect ELISA in 4,6,8 weeks respectively after final vaccination.The splenic lymphocytes of mice were separated and stimulated with PPD to measure their proliferation by flow cytometry,and to evaluate the production of interferon-γ(IFN-γ)in cell suspensions of spleen cells by ELISA.The levels of CD4^+ and CD8^+ T-cell on surface of spleens lymphocyte were determined by flow cytometry.Results PPD could stimulate specific IgG responses in 4 immunity groups,and the average valences of 4 groups are 1∶80,1∶120,1∶160,1∶160;the splenic lymphocyte proliferation reactions and IFN-γproduction weredetectable in 4 immunity groups,and the most significant response occurred in 12 weeks.DNA+IL-12/BCG group and DNA/BCG+IL-12 group induced higher production than BCG group and DNA/BCG group(P〈0.05),and the effects between DNA+IL-12/BCG group and DNA/BCG+IL-12 group had little difference.The numbers of CD4^+ and CD8^+ T-cell in 4 immunity groups were much higher than PBS group(P〈0.05),and DNA+IL-12/BCG group and DNA/BCG+IL-12 group were detected much more CD4^+ and CD8^+ T-cell than BCG group and DNA/BCG group(P〈0.05).The level of T-cell between DNA+IL-12/BCG group and DNA/BCG+IL-12 group had little difference.Conclusion Interleukin 12 associated with the strategy of priming with the combined DNA vaccines and boosting with attenuated M.bovis vaccine(BCG)could induce much stronger specific cellular immunity compared with simple DNA/BCG or attenuated M.bovis vaccine alone.
出处 《四川大学学报(医学版)》 CAS CSCD 北大核心 2008年第4期535-539,共5页 Journal of Sichuan University(Medical Sciences)
基金 教育部重点项目(No.104152) 四川省科技重点项目(03SG022-009)资助
关键词 结核分枝杆菌 AG85A ESAT-6 IL-12 异源初免-加强免疫 Mycobacterium tuberculosis Interleukin 12 Ag85A ESAT-6 Heterologous prime-boost strategy
  • 相关文献

参考文献10

  • 1Peter A. Vaccine strategies against latent tuberculosis infection. Trends in Microbiol:2007;16(1):7-13.
  • 2Young D, Dye C. The development and impact of tuberculosis vaccine. Cell, 2006 ; 124 (4) : 683-687.
  • 3Britton W J, Palendira U. Improving vaccines against tuberculosis. Immunol Cell Biol, 2003 ; 81 (1) : 34-35.
  • 4Song K, Chang Y, Prud’homme GJ. Regulation of T-helper-1 versus T-helper-2 activity and enhancement of tumor immunity by combined DNA-based vaccination and nonviral cytokine gene transfer. Gene Ther,2000;7(6) :481-492.
  • 5龙洋,鲍朗,吴悦涵,赵明才,曾献武,张会东,朱庆平.结核分枝杆菌免疫优势抗原ESAT-6真核表达载体的构建及蛋白表达的鉴定[J].中国呼吸与危重监护杂志,2004,3(3):181-184. 被引量:4
  • 6郝牧,鲍朗,张会东,高蕾,李娅莎.IL-12基因不同亚基真核表达载体的构建及表达[J].细胞与分子免疫学杂志,2006,22(6):698-702. 被引量:2
  • 7Grover A, Ahmed MF, Singh B, et al. A multivalent combination of experimental antituberculosis DNA vaccines based on Ag85B and regions of difference antigens. Microbes Infect, 2006 ; 8 (9-10) : 2390-2399.
  • 8郝牧,鲍朗,高蕾.人IL-12与结核分枝杆菌抗原ESAT-6联合基因疫苗的免疫效果观察[J].微生物学报,2007,47(3):477-481. 被引量:10
  • 9Yoshida S, Tanaka T, Kita Y, et al. DNA vaccine using hemagglutinating virus of Japan-liposome encapsulating combination encodlng mycobacterial heat shock protein 65 and interleukin-12 confers protection against Mycobacterium tuberculosis by T cell activation. Vaccine, 2006; 24 (8) : 1191- 1204.
  • 10Romano M, D'Souza S, Adnet PY, et al. Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low close intravenous challenge with M. tuberculosis H37Rv. Vaccine, 2006 ; 24 (16) : 3353-3364.

二级参考文献31

  • 1陈月,陈政良.白细胞介素12研究新进展[J].细胞与分子免疫学杂志,2005,21(2):261-263. 被引量:12
  • 2郝牧,鲍朗,张会东,高蕾,李娅莎.IL-12基因不同亚基真核表达载体的构建及表达[J].细胞与分子免疫学杂志,2006,22(6):698-702. 被引量:2
  • 3Lang B,Wei C,Huidong Z,et al.Virulence,Immunogenicity,and Protective Efficacy of Two Recombinant Mycobacterium bovis Bacillus Calmette-Guérin Strains Expressing the Antigen ESAT-6 from Mycobacterium tuberculosis.Infect Immun,2003;71:1656~1661
  • 4Fine PE.Variation in protection by BCG:implications of and for heterologous immunity.Lancet,1995;346:1339-1345
  • 5Pym AS,Brodin P,Majlessi L,et al.Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis.Nat Med,2003;9:533-539
  • 6Pym AS,Brodin P,Brosch R,et al.Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti.Mol Microbiol,2002;46:709-717
  • 7Berthet FX,Rasmussen PB,Rosenkrands I,et al.A Mycobacterium tuberculosis operon encoding ESAT-6 and a novel low-molecular-mass culture filtrate protein (CFP-10).Microbiology,1998;144:3195-3203
  • 8Cole ST,Brosch R,Parkhill J,et al.Deciphering the biology of Mycobacterium tuberculosis from the complet genome sequence. Nature,1998;393:537-544
  • 9Husson RN,James BE,Young RA.Gene replacement and expression of foreign DNA in Mycobacterium.J Bacteriol,1990;172:519-524
  • 10Mahairas GG,Sabo PJ,Hickey MJ,et al.Molecular analysis of genetic differences between Mycobacterium bovis BCG and avirulent M.bovis.J Bacteriol,1996;178:1274-1282

共引文献12

同被引文献16

  • 1杨晓敏,董德琼,杨渝浩,李华芬.IL-7和IL-2协同对肺结核患者Th1/Th2平衡调节作用的研究[J].贵州医药,2006,30(4):315-317. 被引量:5
  • 2温武金,肖玲,吴洁文.Th1/Th2免疫与结核性胸膜炎关系的研究进展[J].中国实用内科杂志,2007,27(2):146-148. 被引量:9
  • 3郝牧,鲍朗,高蕾.人IL-12与结核分枝杆菌抗原ESAT-6联合基因疫苗的免疫效果观察[J].微生物学报,2007,47(3):477-481. 被引量:10
  • 4Shao Y, Yang D, Xu W, et al. Epidemiology of anti tuberculosis drug resistance in a chinese population: current BMC Public Health,2011,11:110.
  • 5Lund JM, Hsing I., Pham TT,et al. Coordination of early protective immunity to viral infection by regulatory T cells. Science, 2008,320 : 1220-1224.
  • 6Andersson J, Samarina A, Fink J, et al. Impaired expression of perforin and granulysin in CD8 T cells at the site of infection in human chronic pulmonary tuberculosis. Infect lmmun,2007,75:5210-5222.
  • 7Pym AS, Brodin P, Brosch R,et al. Loss of RD1 contribuled to the attenuation of the live tuberculosis wmcines Mycobacterium bovis BCG and Mycobacterium microti. Mol Microbiol, 2002,46 : 709-717.
  • 8Lowrie DB, Tascon RE, Colston MJ,et al. Towards a DNA vaccine against tuberculosis. Vaccine, 1994,12:1537 -1540.
  • 9Orme IM. Current progress in tuberculosis vaccine development. Vaccine,2005,23:2105-2108.
  • 10Condos R, Rom WN, Schluger NW. Treatment of muhidrug resistant pulmonary tuberculosis with interferon-gamma via aerosol. I.ancet, 1997,349: 1513-1515.

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部